← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #207 OF 1,000 MOST-CITED

Written procedures - holding; distributing

FDA cited this observation 113 times across 106 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Foods113
BY FISCAL YEAR
FY202410
FY202313
FY202219
FY20215
FY20207
FY201911
FY201827
FY201721

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 3.3× the rate of the average FDA-cited firm (27.4% vs 8.3%), across 106 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your Professional access…

How FDA worded it — real examples

You did not make and keep written procedures for holding and distributing operations.

Cisne Enterprises Inc. · Odessa, Texas · Foods · 2024-04-26

You did not make and keep written procedures for holding and distributing operations.

Nature's Innovation, Inc. · Buford, Georgia · Foods · 2024-04-11

You did not make and keep written procedures for holding and distributing operations.

Weleda Inc · Irvington, New York · Foods · 2024-03-22

You did not make and keep written procedures for holding and distributing operations.

Bio Herbal USA · Dunedin, Florida · Foods · 2024-03-22

You did not make and keep written procedures for holding and distributing operations.

Green Sun Products, LLC · Coral Springs, Florida · Foods · 2024-02-29

You did not make and keep written procedures for holding and distributing operations.

Talisman LLC dba American Metabolix · Richardson, Texas · Foods · 2024-01-31

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharmaceutical quality systemFood industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →